Major surgery in severe haemophilia A with inhibitors using a recombinant factor VIIa and activated prothrombin complex concentrate hybrid regimen

• Published in: Haemophilia : the official journal of the World Federation of Hemophilia 2014-07, Vol.20 (4), p.587-592
• Main Authors: van Veen, J. J., Maclean, R. M., Hampton, K. K., Hamer, A., Makris, M.
• Format: Article
• Language: English
• Subjects: activated prothrombin complex concentrate; Adult; Antibodies, Neutralizing - immunology; Appendectomy; Blood Coagulation Factors - immunology; Blood Coagulation Factors - therapeutic use; Drug Therapy, Combination; Factor VIIa - immunology; Factor VIIa - therapeutic use; haemophilia A; Hemophilia A - drug therapy; Hemophilia A - immunology; Hemophilia A - surgery; Humans; inhibitor; Male; Middle Aged; Orchiectomy; Postoperative Period; Recombinant Proteins - immunology; Recombinant Proteins - therapeutic use; rFVIIa; surgery; total hip replacement
• ISSN: 1351-8216; 1365-2516
• DOI: 10.1111/hae.12365

Summary Major surgery in persons with haemophilia A and inhibitors is increasingly being performed. Both recombinant activated factor VII (rFVIIa) and activated prothrombin complex concentrate (APCC) are used to cover surgery but it remains unclear what the optimal dosing schedules are. We describe the use of a hybrid regimen in four inhibitor patients undergoing eight major surgical procedures using rFVIIa in the initial 2–6 postoperative days followed by FEIBA® for the remaining period. All patients were also treated with tranexamic acid while receiving rFVIIa. We performed six major orthopaedic procedures, one emergency orchidectomy and one open appendectomy. The dosing schedules were at the higher end of those described in the literature but within the recommendations of the summary of product characteristics. Despite this, we encountered non‐surgical bleeding in four of eight episodes. Three of these occurred in one individual suggesting a patient factor. The overall outcome was good for all episodes. The hybrid regimen combines flexibility of dose and dosing frequency of rFVIIa in the immediate postoperative setting with the advantage of a reduced dosing frequency with FEIBA® in the subsequent days. This study also emphasizes that surgical procedures in this patient group remain a challenge.